Eden Biodesign Vaccine Expert to Speak at BioProcess International
Conference & Exhibition
Liverpool, UK and RTP, N.C., USA (September 15, 2010) – Eden Biodesign, a globally-
integrated provider of biopharmaceutical process development, cGMP manufacturing and
consultancy services, today announced that Dr. Andrew Clutterbuck, Purification
Development Team Leader for Eden Biodesign Ltd., will speak at the BioProcess
International™ Conference & Exhibition. The Conference will be held at the Providence
Rhode Island Convention Center September 20-24.
On September 22 at 5:00 p.m., as part for the “Process Development and Analytical
Characterization for Vaccine Production” section of the Conference, Dr. Andrew Clutterbuck
will offer a presentation called: “From Bench to Bag: Deployment and Implementation of
Novel Solutions for Vaccine Production.” Specifically, this presentation is a case study in the
development and implementation of a manufacturing process, and it will provide specific
solutions to the manufacture of adenoviral vectors. Dr. Clutterback will also offer a general
approach for other vaccine platforms. More information about this presentation can be
found at www.ibclifesciences.com/bpi/vaccine.xml.
At the BioProcess International Exhibition, Eden Biodesign will be exhibiting in booth #912.
If you would like to meet with Eden representatives at the show, visit
About Eden Biodesign
Eden Biodesign is a globally-integrated biopharmaceutical company offering consultancy,
biopharmaceutical design, process development and cGMP manufacturing services to
leading biotech and pharmaceutical clients around the world. With a reputation for
commercializing biopharmaceutical products and processes, the company offers expertise
and guidance in multiple sectors. Eden Biodesign’s world class facilities and knowledge in
process development, manufacturing, regulatory and technology transfer support ensure
that Eden Biodesign offers much more than a traditional CMO. Find out more at
www.edenbiodesign.com. Eden Biodesign is a wholly owned subsidiary of Watson
Pharmaceuticals Inc. (NYSE: WPI).
John D. Wagner
PropelMG (for Eden)
(919) 796 9984